Preferred Label : Allogeneic CD3- CD19- CD57 NKG2C NK Cells FATE-NK100;
NCIt synonyms : Adaptive NKs Cells FATE-NK100; Adaptive Memory NKs Cells FATE-NK100; Adaptive Memory Natural Killer Cells FATE-NK100;
NCIt definition : A preparation of pharmacologically-enriched, allogeneic natural killer (NK) cells
derived from a related but not completely matched human leukocyte antigen (HLA)-haploidentical
donor that is seropositive for cytomegalovirus (CMV ), with potential cytolytic and
antineoplastic activities. Upon leukapheresis, the donor peripheral blood mononuclear
cells (PBMCs) are treated to remove T-lymphocytes (CD3 ) and B-lymphocytes (CD19 ).
The remaining leukocytes are cultured for 7 days with the cytokine interleukin-15
(IL-15) and a small molecule inhibitor of glycogen synthase kinase 3-beta (GSK3beta)
to generate the adaptive, CD3- CD19- CD57 NKG2C NK cells FATE-NK100 ex vivo. Upon
infusion of the allogeneic CD3- CD19- CD57 NKG2C NK cells FATE-NK100, these cells
selectively recognize and bind to tumor cells, and secrete perforins, granzymes, and
cytokines, which results in cancer cell lysis. Exposure to CMV induces the expression
of the memory-like activating receptor NKG2C and the maturation marker CD57 in the
isolated NK cells, making them more potent than those not pre-exposed to CMV. CD57
both enhances the effector function of NK cells and stimulates CD16-dependent signaling.
Treatment with IL-15 enhances NK cell proliferation and survival. The GSK3beta inhibitor
induces preferential expansion of CD57 NK cells that exhibit enhanced interferon
(IFN)-gamma production.;
Molecule name : FATE-NK100; FATE NK100;
NCI Metathesaurus CUI : CL524941;
Origin ID : C137863;
UMLS CUI : C4527256;
Semantic type(s)
- Cell [UMLS semantic type]
- concept_is_in_subset
